Sandoz Launches Europe’s First Ustekinumab Biosimilar Autoinjector, Pyzchiva®, For Chronic Inflammatory Diseases

Sandoz, a global leader in biosimilar and generic medicines, has launched Pyzchiva® (ustekinumab) in autoinjector form in Europe. This marks the first ustekinumab biosimilar autoinjector to be commercially available in the region. Developed by Samsung Bioepis, Pyzchiva® is approved to treat multiple chronic inflammatory conditions, including plaque psoriasis, psoriatic arthritis, Crohn’s disease, and pediatric plaque psoriasis in patients aged six and older.

Christophe Delenta, President Europe, Sandoz, commented, “Access to medicine does not end when it reaches the hands of the patient. The Pyzchiva® autoinjector, with its thoughtful and advanced features, addresses the real-world needs of patients in managing chronic inflammatory diseases. This launch marks another important milestone as we strengthen our leadership in immunology biosimilars and reaffirm our commitment to pioneering access across Europe’s evolving healthcare landscape.”

The Pyzchiva® autoinjector offers advantages that may improve treatment adherence, such as automatic dosing, reduced injection pain, a compact design, and flexible storage options. Because so many people in Europe have inflammatory diseases such as psoriasis and Crohn’s disease, making sure patients stick to their treatment plans is important for lowering flares and medical costs.

Pyzchiva® is a strategic biosimilar for Sandoz, aligning with its growth ambitions. It has already launched in 23 European markets, with the autoinjector now available in Spain. Sandoz entered into a commercialization agreement with Samsung Bioepis in 2023, giving it rights to market Pyzchiva® in the US, Brazil, UK, Switzerland, and the EEA, while Samsung Bioepis retains responsibility for development, manufacturing, and regulatory compliance.